Health • NHS • Cancer Care • England
By Swikriti Dandotia • Updated: January 2026
Thousands of men in England are set to gain earlier access to abiraterone — a prostate cancer drug that specialists say can reduce the risk of the disease returning and, for some patients, add years of life. The key difference this time isn’t a brand-new discovery. It’s access: after years of debate, the NHS in England is widening eligibility so the medicine can be prescribed earlier for men with high-risk prostate cancer that hasn’t yet spread.
The attention-grabbing detail is cost. Thanks to generic versions, abiraterone is now widely reported to cost the NHS around £2.50 a day for many patients — a fraction of what many people imagine a “life-extending cancer drug” would cost. It’s also a reminder that big gains in outcomes sometimes come not from futuristic therapies, but from getting proven treatments to the right people at the right time.
What exactly is changing?
Abiraterone has been used on the NHS for years, but it has often been associated with later-stage disease. Under the latest NHS England move, clinicians can offer abiraterone earlier — alongside established treatments — to men with high-risk, hormone-sensitive, non-metastatic prostate cancer (meaning the cancer has not yet spread to other parts of the body).
If you want the technical wording, NHS England has published a clinical commissioning policy and supporting documents for “abiraterone acetate and prednisolone for high-risk, hormone sensitive, non-metastatic prostate cancer.” You can read the official policy pack here: NHS England policy documents.
Who could be eligible?
Eligibility is ultimately a clinical decision, but the expanded access is aimed at men who are newly diagnosed with prostate cancer that is considered high risk and still contained (non-metastatic). Many reports estimate that around 7,000–8,000 men a year in England could benefit under the updated approach.
Practically, that means you may hear abiraterone discussed at the same time as other standard treatments such as hormone therapy (androgen deprivation therapy), radiotherapy and — in some cases — additional medicines that support the overall treatment plan. The policy specifically references combining abiraterone with prednisolone, which is commonly used alongside it.
Why abiraterone matters
Prostate cancer is often driven by male hormones (androgens), including testosterone. Abiraterone works by blocking the body’s ability to produce those hormones, effectively starving hormone-sensitive prostate cancer cells of the signals that help them grow. When used for the right patients, clinical evidence suggests it can significantly reduce relapse and lower the risk of death.
This is why campaigners have argued for years that access should not depend on geography or administrative barriers. The expanded rollout in England also helps close a gap many patients and charities have highlighted when comparing treatment access across the UK.
What patients and families should do next
If you or a family member is being treated for prostate cancer in England, the most useful step is simple: ask your specialist team whether abiraterone is appropriate in your case. Not everyone will be eligible, and not everyone will benefit equally — but the conversation matters, especially if you’ve been told your cancer is “high risk” yet still localised or non-metastatic.
- Ask what stage and risk category you fall into, and what that means for treatment choices.
- Ask whether abiraterone plus prednisolone is now being offered in your NHS area under the new policy.
- Ask about monitoring and side effects, especially around blood pressure, liver function and fatigue.
For a plain-English overview of prostate cancer treatment pathways, including hormone therapies, the NHS patient resource is a helpful starting point: NHS: Treatment for prostate cancer.
Why the “£2.50 a day” figure is so important
Health policy decisions often come down to cost versus benefit. The reason abiraterone is back in the spotlight is that the arrival of generic versions has transformed the economics. A drug that once came with a much higher price tag is now far more affordable, making it easier for the NHS to justify broad access — especially when evidence points to fewer relapses and fewer costly interventions later.
It’s also a rare example of a health headline that combines hope with practical policy: expanding a proven treatment, at a low daily cost, to people who stand to gain the most when it’s used earlier.
Health note: This article is for information only and isn’t medical advice. Treatment decisions should be made with your oncology/urology team, who can factor in your diagnosis, other conditions and test results.
Read more on Swikblog.
